Astellas acquires US Ocata Therapeutics for 379 Million USD, specialist for eye diseases

The US company uses human embryonic stem (hES) cells for the generation of retinal pigment epithelium (RPE) thus developing a regenerative medicine for ophthalmology which is injected into the subretinal space for the treatment of atrophy type (dry type) age-related macular degeneration. US experiments are in clinical phase II.

Astellas news release, November 10, 2015

Most popular posts: